Medpace (MEDP)
(Delayed Data from NSDQ)
$397.56 USD
-9.59 (-2.36%)
Updated Apr 24, 2024 03:59 PM ET
After-Market: $398.06 +0.50 (0.13%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth A Momentum A VGM
Income Statements
Fiscal Year end for Medpace Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1,886 | 1,460 | 1,142 | 926 | 861 |
Cost Of Goods | 638 | 535 | 441 | 354 | 321 |
Gross Profit | 1,248 | 925 | 701 | 572 | 540 |
Selling & Adminstrative & Depr. & Amort Expenses | 911 | 646 | 503 | 404 | 413 |
Income After Depreciation & Amortization | 337 | 279 | 199 | 167 | 127 |
Non-Operating Income | -1 | 7 | 3 | 1 | -1 |
Interest Expense | 0 | 3 | 0 | 0 | 2 |
Pretax Income | 336 | 283 | 202 | 169 | 125 |
Income Taxes | 53 | 37 | 20 | 23 | 24 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 283 | 245 | 182 | 145 | 100 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 283 | 245 | 182 | 145 | 100 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 363 | 300 | 219 | 186 | 151 |
Depreciation & Amortization (Cash Flow) | 26 | 22 | 20 | 19 | 23 |
Income After Depreciation & Amortization | 337 | 279 | 199 | 167 | 127 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 31.84 | 33.67 | 37.70 | 37.71 | 37.58 |
Diluted EPS Before Non-Recurring Items | 8.88 | 7.28 | 4.81 | 4.00 | 3.02 |
Diluted Net EPS (GAAP) | 8.88 | 7.28 | 4.81 | 3.84 | 2.67 |
Fiscal Year end for Medpace Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 498.40 | 492.50 | 460.87 | 434.07 |
Cost Of Goods | NA | 164.29 | 164.36 | 158.53 | 151.07 |
Gross Profit | NA | 334.11 | 328.14 | 302.34 | 283.01 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 246.79 | 243.23 | 223.95 | 196.80 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 87.32 | 84.91 | 78.39 | 86.21 |
Non-Operating Income | NA | 1.54 | -1.60 | -1.28 | 0.69 |
Interest Expense | NA | -1.84 | 0.11 | 1.37 | 0.86 |
Pretax Income | NA | 90.71 | 83.20 | 75.74 | 86.03 |
Income Taxes | NA | 12.41 | 12.65 | 14.68 | 13.14 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 78.30 | 70.55 | 61.07 | 72.89 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 78.30 | 70.55 | 61.07 | 72.89 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 31.83 | 31.76 | 31.58 | 32.16 |
Diluted EPS Before Non-Recurring Items | NA | 2.46 | 2.22 | 1.93 | 2.27 |
Diluted Net EPS (GAAP) | NA | 2.46 | 2.22 | 1.93 | 2.27 |